WO2009090651A3 - Ligands des molécules hla-b2705 du complexe majeur d'histocompatibilité, utilisés à des fins de diagnostic et de traitement - Google Patents

Ligands des molécules hla-b2705 du complexe majeur d'histocompatibilité, utilisés à des fins de diagnostic et de traitement Download PDF

Info

Publication number
WO2009090651A3
WO2009090651A3 PCT/IL2009/000067 IL2009000067W WO2009090651A3 WO 2009090651 A3 WO2009090651 A3 WO 2009090651A3 IL 2009000067 W IL2009000067 W IL 2009000067W WO 2009090651 A3 WO2009090651 A3 WO 2009090651A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
therapy
major histocompatibility
histocompatibility complex
ligands useful
Prior art date
Application number
PCT/IL2009/000067
Other languages
English (en)
Other versions
WO2009090651A2 (fr
Inventor
Lilach Halevi
Arie Admon
Eilon Barnea
Ilan Beer
Original Assignee
Technion Research And Development Foundation Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Research And Development Foundation Ltd. filed Critical Technion Research And Development Foundation Ltd.
Publication of WO2009090651A2 publication Critical patent/WO2009090651A2/fr
Publication of WO2009090651A3 publication Critical patent/WO2009090651A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne des complexes HLA-B2705-peptide multimères, et leur utilisation dans le diagnostic et le traitement du cancer et d'autres troubles autoimmuns.
PCT/IL2009/000067 2008-01-15 2009-01-15 Ligands des molécules hla-b2705 du complexe majeur d'histocompatibilité, utilisés à des fins de diagnostic et de traitement WO2009090651A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2105108P 2008-01-15 2008-01-15
US61/021,051 2008-01-15

Publications (2)

Publication Number Publication Date
WO2009090651A2 WO2009090651A2 (fr) 2009-07-23
WO2009090651A3 true WO2009090651A3 (fr) 2009-12-03

Family

ID=40885729

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2009/000067 WO2009090651A2 (fr) 2008-01-15 2009-01-15 Ligands des molécules hla-b2705 du complexe majeur d'histocompatibilité, utilisés à des fins de diagnostic et de traitement

Country Status (1)

Country Link
WO (1) WO2009090651A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2638823A1 (fr) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Sequences polynucleotidiques et polypeptidiques intervenant dans le processus de remodelage osseux
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CN102481333B (zh) 2009-09-03 2017-07-14 东丽株式会社 免疫诱导剂
US8946379B2 (en) 2009-09-24 2015-02-03 The Regents Of The University Of California Bladder cancer specific ligand peptides
CN103764668B (zh) 2011-07-09 2016-08-17 加利福尼亚大学董事会 白血病干细胞靶向配体及应用方法
IN2014KN02933A (fr) 2012-07-19 2015-05-08 Alethia Biotherapeutics Inc
US20170232084A1 (en) 2013-04-26 2017-08-17 Enzo Biochem Inc. Immune modulation for the treatment of age-related macular degeneration
US20140322188A1 (en) * 2013-04-26 2014-10-30 Enzo Biochem, Inc. Tolerizing treatments for autoimmune disease
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
PT3424518T (pt) * 2016-03-02 2021-09-22 Toray Industries Indutor de imunidade
US20210215707A1 (en) * 2018-08-14 2021-07-15 Board Of Regents, The University Of Texas System Single molecule sequencing peptides bound to the major histocompatibility complex
GB202217153D0 (en) * 2022-11-16 2022-12-28 Carocell Bio Ltd Peptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998012221A1 (fr) * 1996-09-18 1998-03-26 Gerhild Wildner Peptides servant d'agent diagnostique et d'agent therapeutique pour les maladies auto-immunes
WO1999058557A2 (fr) * 1998-05-11 1999-11-18 Isis Innovation Limited Nouvelle molecule et methode diagnostique
US20050053918A1 (en) * 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998012221A1 (fr) * 1996-09-18 1998-03-26 Gerhild Wildner Peptides servant d'agent diagnostique et d'agent therapeutique pour les maladies auto-immunes
WO1999058557A2 (fr) * 1998-05-11 1999-11-18 Isis Innovation Limited Nouvelle molecule et methode diagnostique
US20050053918A1 (en) * 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GIQUEL BENOIT ET AL: "Two HLA-B27 alleles differently associated with spondylarthritis, B*2709 and B*2705, display similar intracellular trafficking and oligomer formation", ARTHRITIS & RHEUMATISM, vol. 56, no. 7, July 2007 (2007-07-01), pages 2232 - 2243, XP002547408, ISSN: 0004-3591 *

Also Published As

Publication number Publication date
WO2009090651A2 (fr) 2009-07-23

Similar Documents

Publication Publication Date Title
WO2009090651A3 (fr) Ligands des molécules hla-b2705 du complexe majeur d'histocompatibilité, utilisés à des fins de diagnostic et de traitement
PL2358697T3 (pl) Związki izoindolinowe do zastosowania w leczeniu raka
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
WO2010003520A3 (fr) Immunothérapie antitumorale
EP2590671A4 (fr) Immunoglobulines à domaine variable double et leurs utilisations
TN2013000227A1 (en) Use of sigma ligands in bone cancer pain
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
PL2847225T3 (pl) Przeciwciała przeciwko klaudynie 18.2 przydatne w diagnostyce nowotworów
MY163368A (en) Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use
MX2013004979A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2013002270A (es) Inmonoglubinas de dominio variable doble y usos de las mismas.
TW201206473A (en) Dual variable domain immunoglobulins and uses thereof
WO2012062925A3 (fr) Composés et procédés de traitement de la douleur
MX2020012426A (es) Anticuerpos anti-cd38.
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
IN2012DN00863A (fr)
MX347164B (es) Anticuerpos anti-il-36r.
WO2011143318A3 (fr) Anticorps anti-fgfr2
EP3461847A8 (fr) Anticorps humanises contre liv-1 et leurs utilisations pour traiter le cancer
WO2010115118A3 (fr) Procédés de préparation et d'utilisation de complexes chaperons multiples-antigène
MY146112A (en) Long-term feed - cancer patient
WO2012061390A3 (fr) Compositions et procédés thérapeutiques
EP2576575A4 (fr) Composés conjugués prostaglandine-bisphosphonate, leurs méthodes de fabrication et leurs utilisations
ZA201209452B (en) Gold complexes for use in the treatment of cancer
EP2547666A4 (fr) Conjugués de 1,4,7-triaza-cyclononanes, complexes métalliques dinucléaires de ces conjugués, et procédés d'utilisation des 1,4,7-triaza-cyclononanes et des conjugués

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09702550

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 09702550

Country of ref document: EP

Kind code of ref document: A2